CD44 and neoplasm: At day 125 (45 days after tumor rechallenging), mice spleens showed a significant increase in CD3+ CD44+ memory cells, as well as a higher percentage of central memory CD4+ and both effector memory CD4+ and CD8+ T cells, indicating a robust immunologic memory induced by PTT, leading to a survival rate of 80% (4/5) after 125 days.